Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | See Remarks | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,938 |
Last balance in matching sequence
After 2026-10-02 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2026-10-01 · Exercise / conversion · Acquired 413 · Balance 10,351 F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 2 · 2026-10-01 · Sale · Disposed 413 · Balance 9,938 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.30 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 3 · 2026-10-02 · Exercise / conversion · Acquired 24,587 · Balance 34,525 F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 4 · 2026-10-02 · Sale · Disposed 15,843 · Balance 18,682 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.38 to $116.36 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 5 · 2026-10-02 · Sale · Disposed 8,744 · Balance 9,938 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.39 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27 · Expires 2027-02-10 | Direct | 66,573 |
Reported balance
After 2026-10-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-10-01 · Exercise / conversion · Disposed 413 · Balance 66,573 F11: Fully exercisable. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27 · Expires 2027-02-10 | Direct | 41,986 |
Reported balance
After 2026-10-02 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-10-02 · Exercise / conversion · Disposed 24,587 · Balance 41,986 F11: Fully exercisable. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,147 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,147 F6: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 20,570 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 20,570 F7: Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 40,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 40,000 F8: Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 34,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 34,000 F9: Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 10,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 10,000 F10: Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.30 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.38 to $116.36 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.39 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F7: Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
F8: Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F9: Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F10: Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F11: Fully exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2021 Filed Oct 5, 2021 22:17 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 637 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-21-039272 · doc4.xml · derivative · entry 8 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,602 Underlying: Common Stock · 637 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 22:17 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 637 | $20.00 | $12,740.00 |
DisclosureSEC source: 0000899243-21-039272 · doc4.xml · nonDerivative · entry 4 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,024 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 22:17 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 637 | $3.29 | $2,095.73 |
DisclosureSEC source: 0000899243-21-039272 · doc4.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 22:17 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,363 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-21-039272 · doc4.xml · derivative · entry 7 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,239 Underlying: Common Stock · 24,363 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 22:17 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 24,363 | $20.00 | $487,374.51 |
DisclosureSEC source: 0000899243-21-039272 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,024 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $20.00 to $20.05 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 22:17 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 24,363 | $3.29 | $80,154.27 |
DisclosureSEC source: 0000899243-21-039272 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-21-035138 · doc4.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,602 Underlying: Common Stock · 25,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 25,000 | $21.40 | $534,930.00 |
DisclosureSEC source: 0000899243-21-035138 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,024 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $21.38 to $21.445 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 25,000 | $3.29 | $82,250.00 |
DisclosureSEC source: 0000899243-21-035138 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-21-031793 · doc4.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,602 Underlying: Common Stock · 25,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 25,000 | $21.18 | $529,420.00 |
DisclosureSEC source: 0000899243-21-031793 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,024 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $21.12 to $21.335 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 25,000 | $3.29 | $82,250.00 |
DisclosureSEC source: 0000899243-21-031793 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 21:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0000899243-21-028328 · doc4.xml · derivative · entry 4 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 10,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 21:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 10,000 | $2.24 | $22,400.00 |
DisclosureSEC source: 0000899243-21-028328 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2021 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 6 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 40,000 F2 · kind: Transfer of shares without consideration to the Sean and Molly Maduck Living Trust. F3 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| July 13, 2021 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,622 F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 21:29 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-21-028014 · doc4.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,602 Underlying: Common Stock · 25,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 21:29 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 25,000 | $22.19 | $554,692.50 |
DisclosureSEC source: 0000899243-21-028014 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,024 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $22.17 to $22.25 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 21:29 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 25,000 | $3.29 | $82,250.00 |
DisclosureSEC source: 0000899243-21-028014 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 01:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,989 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-21-006784 · doc4.xml · derivative · entry 8 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,602 Underlying: Common Stock · 8,989 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 01:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 8,989 | $28.25 | $253,903.29 |
DisclosureSEC source: 0000899243-21-006784 · doc4.xml · nonDerivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,024 F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $28.21 to $28.25 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 01:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 8,989 | $3.29 | $29,573.81 |
DisclosureSEC source: 0000899243-21-006784 · doc4.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 01:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,400 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-21-006784 · doc4.xml · derivative · entry 7 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,591 Underlying: Common Stock · 3,400 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 01:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 3,400 | $29.78 | $101,248.94 |
DisclosureSEC source: 0000899243-21-006784 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,024 F1 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $29.7783 to $29.7826 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 01:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 3,400 | $3.29 | $11,186.00 |
DisclosureSEC source: 0000899243-21-006784 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 22:22 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $29.41 | $0.00 |
DisclosureSEC source: 0000899243-21-005192 · doc4.xml · derivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-02-04 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 5, 2021, so that the total number of shares subject to this option becomes fully vested and exercisable on February 5, 2025. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 22:11 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $15.82 | $0.00 |
DisclosureSEC source: 0000899243-20-019203 · doc4.xml · derivative · entry 1 Maduck Sean · CIK 0001698310 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-07-13 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of July 1, 2020, so that the total number of shares subject to this option becomes fully vested and exercisable on July 1, 2024. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 22:13 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0000899243-20-004046 · doc4.xml · derivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-02-06 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 7, 2020, so that the total number of shares subject to this option becomes fully vested and exercisable on February 7, 2024. Read SEC document |
| February 08, 2019 Filed Feb 13, 2019 02:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0000899243-19-003381 · doc4.xml · derivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-02-07 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 8, 2019, so that the total number of shares subject to this option becomes fully vested and exercisable on February 8, 2023. Read SEC document |
| December 13, 2018 Filed Dec 15, 2018 01:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0000899243-18-031133 · doc4.xml · derivative · entry 9 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 10,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 13, 2018 Filed Dec 15, 2018 01:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 10,000 | $2.24 | $22,400.00 |
DisclosureSEC source: 0000899243-18-031133 · doc4.xml · nonDerivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2018 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 30,000 F2 · kind: Transfer of shares without consideration to the Sean and Molly Maduck Living Trust. F3 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| December 13, 2018 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,622 F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 12, 2018 Filed Dec 15, 2018 01:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,009 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-18-031133 · doc4.xml · derivative · entry 8 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,991 Underlying: Common Stock · 15,009 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 18, 2015, so that the total number of shares subject to this option becomes fully vested and exercisable on February 18, 2019. Read SEC document |
| December 12, 2018 Filed Dec 15, 2018 01:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 44,991 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0000899243-18-031133 · doc4.xml · derivative · entry 7 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,009 Underlying: Common Stock · 44,991 shares Expires 2024-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 12, 2018 Filed Dec 15, 2018 01:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 60,000 | $19.01 | $1,140,366.00 |
DisclosureSEC source: 0000899243-18-031133 · doc4.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,024 F1 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $18.75 to $19.48 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| December 12, 2018 Filed Dec 15, 2018 01:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 15,009 | $3.29 | $49,379.61 |
DisclosureSEC source: 0000899243-18-031133 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2018 Filed Dec 15, 2018 01:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 44,991 | $2.61 | $117,426.51 |
DisclosureSEC source: 0000899243-18-031133 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2018 Filed May 17, 2018 21:27 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0000899243-18-013255 · doc4.xml · derivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 10,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 15, 2018 Filed May 17, 2018 21:27 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 10,000 | $2.24 | $22,400.00 |
DisclosureSEC source: 0000899243-18-013255 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2018 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 20,000 F2 · kind: Transfer of shares without consideration to the Sean and Molly Maduck Living Trust. F3 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| May 15, 2018 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,622 F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 07, 2018 Filed Feb 10, 2018 01:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $16.52 | $0.00 |
DisclosureSEC source: 0000899243-18-003467 · doc4.xml · derivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-02-07 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 7, 2018, so that the total number of shares subject to this option becomes fully vested and exercisable on February 7, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.